Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1

{
  "publication_number": "US9540371B2",
  "country": "US",
  "kind": "B2",
  "title": "Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1",
  "abstract": "In one aspect, the invention relates to 3-benzylquinazolin-4(3H)-one analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M 1 (mAChR M 1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. Exemplary 3-benzylquinazolin-4(3H)-one compounds include compounds of formula (I):",
  "claims": [
    "1. A compound having a structure represented by a formula: wherein: Q 1 is selected from N and CR 1a; Q 2 is CR 1b; Q 3 is selected from N and CR 1c; Q 4 is selected from N and CR 1d; provided that 0 or 1 of Q 1, Q 3, and Q 4 is N; each of R 1a, R 1b, R 1c, and R 1d, when present, is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1-C6 alkoxy, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkylamino, C1-C6 haloalkyl-oxy-C1-C6 alkyl, C1-C6 polyhaloalkyl-oxy-C1-C6 alkyl, and C1-C6 dialkylamino; Q 5 is selected from N and CR 2a; Q 6 is selected from N and CR 2b; Q 7 is selected from N and CR 2c; Q 8 is selected from N and CR 2d; provided that 0, 1 or 2 of Q 5, Q 6, Q 7, and Q 8 are N; each of R 2a, R 2b, R 2c, and R d, when present, is independently selected from hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1-C6 alkoxy, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkylamino, C1-C6 haloalkyl-oxy C1-C6 alkyl, C1-C6 polyhaloalkyl-oxy-C1-C6 alkyl, C1-C6 dialkylamino, - C(OH)R 20a R 20b, and - SO 2 R 30; each of R 20a and R 20b is independently selected from hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, and C1-C3 polyhaloalkyl; R 30 is selected from C1-C3 alkyl, C1-C3 haloalkyl, and C1-C3 polyhaloalkyl; R 3 is selected from hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and Ar 1; wherein Ar 1 is selected from phenyl, indenyl, and naphthalenyl; wherein Ar 1 is substituted with 0-3 substituents selected from halogen, hydroxyl, cyano, - NH 2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1-C6 alkylamino, and C1-C6 dialkylamino; R 4 is selected from Ar 2, - L 2 - Ar 2, and Cy 1; L 2 is selected from - CR 8a R 8b -, - O -, - NR 9 -, - S -, - (S═O) -, and - (SO 2) -; each of R 8a and R 8b is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 polyhaloalkyl; R 9 is selected from hydrogen and C1-C6 alkyl; Ar 2 is selected from benzodioxolyl, benzofuranyl, benzoimidazolyl, benzoisoxazolyl, benzooxadiazolyl, benzooxazolyl, benzothiazolyl, benzothiophenyl, dihydrobenzodioxinyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, furanyl, furopyridinyl, imidazolyl, imidazopyrazinyl, imidazopyridinyl, indazolyl, indolinyl, indolyl, isoindolinyl, isoquinolinyl, naphthyridinyl, oxadiazolyl, oxazolyl, oxoindolinyl, 2′-oxospiro[1,3]dioxolane-2,3′-indolinyl, pyrazinyl, pyridinyl, pyrimidinyl, pyrrolopyridinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydroquinolinyl, thiadiazolyl, thiazolyl, triazopyridinyl, and triazolyl; wherein Ar 2 is substituted with 0-3 substituents selected from halogen, hydroxyl, cyano, - NH 2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1-C6 alkylamino, and C1-C6 dialkylamino; or Ar 2 is pyrazolyl substituted with 1-3 substituents selected from halogen, hydroxyl, cyano, - NH 2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1-C6 alkylamino, and C1-C6 dialkylamino; Cy 1 is C2-C5 heterocycloalkyl or C2-C5 heterocycloalkenyl; wherein Cy 1 is substituted with 0-3 substituents selected from halogen, hydroxyl, cyano, - NH 2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 polyhaloalkyl, C1C6 alkylamino, and C1-C6 dialkylamino, and wherein two of the substituents are optionally covalently bonded, and together with the intermediate atoms, comprise a 3- to 6-membered fused ring group; and each of R 7a and R 7b is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 polyhaloalkyl; or a pharmaceutically acceptable salt, thereof.",
    "2. The compound of claim 1, wherein each of R 1a, R 1b, R 1c, and R 1d, when present, is hydrogen.",
    "3. The compound of claim 1, having a structure represented by a formula:",
    "4. The compound of claim 1, having a structure represented by a formula:",
    "5. The compound of claim 1, having a structure represented by a formula:",
    "6. The compound of claim 1, having a structure represented by a formula:",
    "7. The compound of claim 1, having a structure selected from:",
    "8. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.",
    "9. A method for modulating muscarinic acetylcholine receptor activity in a mammal; the method comprising the step of administering to the mammal an effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt thereof.",
    "10. The method of claim 9, wherein the mammal has a disorder selected from psychosis, schizophrenia, conduct disorder, disruptive behavior disorder, bipolar disorder, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders, severe major depressive disorder, mood disorders associated with psychotic disorders, acute mania, depression associated with bipolar disorder, mood disorders associated with schizophrenia, behavioral manifestations of mental retardation, conduct disorder, autistic disorder, movement disorders, Tourette's syndrome, akinetic-rigid syndrome, movement disorders associated with Parkinson's disease, tardive dyskinesia, drug induced and neurodegeneration based dyskinesias, attention deficit hyperactivity disorder, cognitive disorders, dementias, and memory disorders.",
    "11. The method of claim 9, wherein the mammal has a disorder selected from Alzheimer's disease, schizophrenia, a sleep disorder, a pain disorder and a cognitive disorder.",
    "12. The method of claim 11, wherein the disorder is Alzheimer's disease."
  ],
  "cpc": [
    "C07D 471/04",
    "C07D 401/10",
    "C07D 403/10"
  ],
  "assignees": [
    "UNIV VANDERBILT"
  ],
  "filing_date": "2014-04-28",
  "publication_date": "2017-01-10",
  "grant_date": "2017-01-10",
  "priority_date": "2013-04-29",
  "application_number": "US-201414787722-A",
  "family_id": "51843875",
  "citations": [
    "US2006247244A1",
    "US2011112119A1",
    "US2013123236A1",
    "US5962457A",
    "WO2013103931A1"
  ]
}